CDCailin E. Deal

Cailin E. Deal

*This is an algorithmically generated author record based on publicly available information.

Cailin E. Deal has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions

    by Cailin E. Deal, Angelene F. Richards, Tracy Yeung, Max J. Maron, Ziqiu Wang, Yen-Ting Lai, Brian R. Fritz, Sunny Himansu, Elisabeth Narayanan, Ding Liu, et al.


  • Open Access

    mRNA delivery of dimeric human IgA protects mucosal tissues from bacterial infection

    by Cailin E. Deal, Angelene F. Richards, Tracy Yeung, Max J. Maron, Ziqiu Wang, Yen-Ting Lai, Brian R. Fritz, Sunny Himansu, Elisabeth Narayanan, Ding Liu, et al.

    Monoclonal antibody (mAb) therapy is a promising infectious disease intervention strategy but is limited to IgG1 isotypes that have restricted access to mucosal sites. IgA is well-established as the predominant antibody isotype in mucosal secretions but is clinically underutilized. To enable development of IgA-based mAbs, we exploited mRNA platform technology and demonstrated expression of functional, antigen-specific IgA (IgA mRNA ) that can limit bacterial invasion in the intestine and prevent colonization in the lung. Moreover, in vivo IgA mRNA had enhanced serum half-life and a greater degree of sialylation than a recombinantly produced IgA. The results underscore the potential of mRNA-based platforms to deliver protective human mAbs to mucosal surfaces and open new avenues to combat infectious diseases in the face of pervasive antibiotic resistance. One Sentence Summary: mRNA-encoded human monoclonal IgA traffics to mucosal tissues and provides protection against bacterial challenge


  • Open Access

    Advancements in mRNA Encoded Antibodies for Passive Immunotherapy

    by Cailin E. Deal, Andrea Carfi, Obadiah J. Plante

    Monoclonal antibodies are the fastest growing therapeutic class in medicine today. They hold great promise for a myriad of indications, including cancer, allergy, autoimmune and infectious diseases. However, the wide accessibility of these therapeutics is hindered by manufacturing and purification challenges that result in high costs and long lead times. Efforts are being made to find alternative ways to produce and deliver antibodies in more expedient and cost-effective platforms. The field of mRNA has made significant progress in the last ten years and has emerged as a highly attractive means of encoding and producing any protein of interest in vivo. Through the natural role of mRNA as a transient carrier of genetic information for translation into proteins, in vivo expression of mRNA-encoded antibodies offer many advantages over recombinantly produced antibodies. In this review, we examine both preclinical and clinical studies that demonstrate the feasibility of mRNA-encoded antibodies and discuss the remaining challenges ahead.